Janssen-Cilag
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Janssen-Cilag sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Janssen-Cilag: 4 sponsored US clinical trials, 1 recruiting.
Janssen-Cilag sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 3 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Perianal Crohns Disease, with 1 trials.
Upper-quartile sponsor footprint
Janssen-Cilag sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
NCT06408935
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095
A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
NCT04035226
A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease
NCT03782376
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 3 |
Therapeutic Areas
Where Janssen-Cilag enrollment is open (later-stage tilt)
1 recruiting of 4 indexed (25% open); 2 completed (50%).
Phase mix: 3 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Perianal Crohns Disease (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Janssen-Cilag: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Janssen-Cilag sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
Related
What to do with this Janssen-Cilag page
4 registered trials is a research-attention snapshot, not an endorsement of Janssen-Cilag or any single study.
- 1 of Janssen-Cilag's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Perianal Crohns Disease is the condition Janssen-Cilag studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Perianal Crohns Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Janssen-Cilag pipeline card: 4 registered trials from official public datasets.Report a data error.